The role of intravenous immunoglobulin in the treatment of multiple sclerosis

Journal of the Neurological Sciences

Volumn 206, Issue 2, 2003, Pages 123-130

  Sorensen, Per Soelberg ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Controlled trials; Disease progression; Immunoglobulin G; Intravenous immunoglobulin; MRI; Multiple sclerosis; Multiple sclerosis drug therapy; Relapses

Indexed keywords

BETA INTERFERON; GADOLINIUM; GLATIRAMER; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PLACEBO; PREDNISONE;

ANTIINFLAMMATORY ACTIVITY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DEEP VEIN THROMBOSIS; DEPRESSION; DISABILITY; DISEASE COURSE; DISEASE EXACERBATION; DOSIMETRY; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; ECZEMA; ENCEPHALOMYELITIS; HEADACHE; HEPATITIS C; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; LUNG EMBOLISM; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PUERPERIUM; RASH; RELAPSE; REMISSION; REMYELINIZATION; REVIEW; SIDE EFFECT; SYMPTOM; TREATMENT OUTCOME; VISUAL IMPAIRMENT;

EID: 0037441359     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(02)00343-X     Document Type: Article

References (61)

1. van der Meche F.G., Schmitz P.I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N. Engl. J. Med. 326:1992;1123-1129.
2. van den Berg L.H., Franssen H., Van Doorn P.A., Wokke J.H. Intravenous immunoglobulin treatment in lower motor neuron disease associated with highly raised anti-GM1 antibodies. J. Neurol. Neurosurg. Psychiatry. 63:1997;674-677.
3. Dyck P.J., Litchy W.J., Kratz K.M., Suarez G.A., Low P.A., Pineda A.A.et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 36:1994;838-845.
4. Hafler D.A., Brod S.A., Weiner H.L. Immunoregulation in multiple sclerosis. Res. Immunol. 140:1989;233-239.
5. Lucchinetti C.F., Bruck W., Rodriguez M., Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 6:1996;259-274.
6. Storch M., Lassmann H. Pathology and pathogenesis of demyelinating diseases. Curr. Opin. Neurol. 10:1997;186-192.
7. Bruck W., Bitsch A., Kolenda H., Bruck Y., Stiefel M., Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann. Neurol. 42:1997;783-793.
8. Storch M.K., Piddlesden S., Haltia M., Iivanainen M., Morgan P., Lassmann H. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann. Neurol. 43:1998;465-471.
9. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47:2000;707-717.
10. Dalakas M.C. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology. 51(6 Suppl. 5):1998;S2-S8.
11. Dalakas M.C. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve. 22:1999;1479-1497.
12. Kaveri S.V., Mouthon L., Kazatchkine M.D. Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases. J. Neurol. Neurosurg. Psychiatry. 57:1994;6-8. [Supplement].
13. Kazatchkine M.D., Bellon B., Kaveri S.V. Mechanisms of action of intravenous immunoglobulin (IVIG). Mult. Scler. 6(Suppl. 2):2000;S24-S26.
14. Kazatchkine M.D., Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 345:2001;747-755.
15. Andersson J.P., Andersson U.G. Human intravenous immunoglobulin modulates monokine production in vitro. Immunology. 71:1990;372-376.
16. Ross C., Svenson M., Nielsen H., Lundsgaard C., Hansen M.B., Bendtzen K. Increased in vivo antibody activity against interferon alpha, interleukin-1alpha, and interleukin-6 after high-dose Ig therapy. Blood. 90:1997;2376-2380.
17. Frank M.M., Basta M., Fries L.F. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin. Immunol. Immunopathol. 62:1992;S82-S86.
18. Bieber A., Asakura K., Warrington A., Kaveri S.V., Rodriguez M. Antibody-mediated remyelination: relevance to multiple sclerosis. Mult. Scler. 6(Suppl. 2):2000;S1-S5.
19. Lucchinetti C.F., Noseworthy J.H., Rodriguez M. Promotion of endogenous remyelination in multiple sclerosis. Mult. Scler. 3:1997;71-75.
20. Miller D.J., Asakura K., Rodriguez M. Experimental strategies to promote central nervous system remyelination in multiple sclerosis: insights gained from the Theiler's virus model system. J. Neurosci. Res. 41:1995;291-296.
21. Rodriguez M., Lennon V.A., Benveniste E.N., Merrill J.E. Remyelination by oligodendrocytes stimulated by antiserum to spinal cord. J. Neuropathol. Exp. Neurol. 46:1987;84-95.
22. Rodriguez M., Lennon V.A. Immunoglobulins promote remyelination in the central nervous system. Ann. Neurol. 27:1990;12-17.
23. Rodriguez M., Miller D.J., Lennon V.A. Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology. 46:1996;538-545.
24. van Engelen B.G., Miller D.J., Pavelko K.D., Hommes O.R., Rodriguez M. Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 57:1994;65-68. [Supplement].
25. Wurster U., Haas J. Passage of intravenous immunoglobulin and interaction with the CNS. J. Neurol. Neurosurg. Psychiatry. 57:1994;21-25. [Supplement].
26. Sorensen P.S., Wanscher B., Jensen C.V., Schreiber K., Blinkenberg M., Ravnborg M.et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology. 50:1998;1273-1281.
27. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H.et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:2000;916-919.
28. Sorensen P.S. Intravenous immunoglobulin G therapy: effects of acute and chronic treatment in multiple sclerosis. Mult. Scler. 1:1996;349-352.
29. Rothfelder U., Neu I., Pelka R. Therapy of multiple sclerosis with immunoglobulin G. MMW, Munch Med. Wochenschr. 124:1982;74-78.
30. Schuller E., Govaerts A. First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur. Neurol. 22:1983;205-212.
31. Schuller E., Lambin P., Deloche G. Long-term treatment of multiple sclerosis with IgG immunotherapy. Pathol. Biol. (Paris). 44:1996;710-715.
32. Cook S.D., Troiano R., Rohowsky Kochan C., Jotkowitz A., Bielory L., Mehta P.D.et al. Intravenous gamma globulin in progressive MS. Acta Neurol. Scand. 86:1992;171-175.
33. Achiron A., Pras E., Gilad R., Ziv I., Mandel M., Gordon C.R.et al. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch. Neurol. 49:1992;1233-1236.
34. Achiron A., Cohen I.R., Lider O., Melamed E. Intravenous immunoglobulin treatment in multiple sclerosis. Isr. J. Med. Sci. 31:1995;7-9.
35. Francis G.S., Freedman M.S., Antel J.P. Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study. Mult. Scler. 3:1997;370-376.
36. Kalanie H., Tabatabai S.S. Combined immunoglobulin and azathioprine in multiple sclerosis. Eur. Neurol. 39:1998;178-181.
37. Fazekas F., Deisenhammer F., Strasser Fuchs S., Nahler G., Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet. 349:1997;589-593.
38. Strasser-Fuchs S., Fazekas F., Deisenhammer F., Nahler G., Mamoli B. The Austrian Immunoglobulin in MS (AIMS) study: final analysis. Mult. Scler. 6(Suppl. 2):2000;S9-S13.
39. Poser C.M. Intravenous immunoglobulin for multiple sclerosis. Lancet. 349(9059):1997;1177-1178.
40. Achiron A., Gabbay U., Gilad R., Hassin B.S., Barak Y., Gornish M.et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology. 50:1998;398-402.
41. Sorensen P.S., Wanscher B., Schreiber K., Blinkenberg M., Jensen C.V., Ravnborg M. A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: preliminary results. Mult. Scler. 3:1997;145-148.
42. Lewanska M., Zajdel M.S., Selmaj K. Low dose of intravenous immunoglobulins is equally effective in multiple sclerosis as high dose. Clinical and MRI assessment. Eur. J. Neurol. 9:2002;565-572.
43. Achiron A., Rotstein Z., Noy S., Mashiach S., Dulitzky M., Achiron R. Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J. Neurol. 243:1996;25-28.
44. Haas J. High dose IVIG in the post partum period for prevention of exacerbations in MS. Mult. Scler. 6(Suppl. 2):2000;S18-S20.
45. Soukop W., Tschabitscher H. Gamma globulin therapy in multiple sclerosis. Theoretical considerations and initial clinical experiences with 7S immunoglobulins in MS therapy. Wien Med. Wochenschr. 136:1986;477-480.
46. Sahlas D.J., Miller S.P., Guerin M., Veilleux M., Francis G. Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology. 54(6):2000;1370-1372.
47. Nos C., Comabella M., Tintore M., Rio J., Codina A., Montalban X. Rovira A: high dose intravenous immunoglobulin does not improve abnormalities in the blood-brain barrier during acute relapse of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 61:1996;418.
48. van Engelen B.G., Hommes O.R., Pinckers A., Cruysberg J.R., Barkhof F., Rodriguez M. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann. Neurol. 32:1992;834-835.
49. Noseworthy J.H., O'Brien P.C., Petterson T.M., Weis J., Stevens L., Peterson W.K.et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology. 56:2001;1514-1522.
50. Noseworthy J.H., O'Brien P.C., Weinshenker B.G., Weis J.A., Petterson T.M., Erickson B.J.et al. IV immunoglobulin does not reverse established weakness in MS. Neurology. 55:2000;1135-1143.
51. Stangel M., Boegner F., Klatt C.H., Hofmeister C., Seyfert S. Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 68:2000;89-92.
52. Sorensen P.S., Pozilli C., Kölmel H.W., Fernandez O., Blumhardt L., O'Connor P.et al. European study on intravenous immunoglobulin in multiple sclerosis (ESIMS): design of the study and preliminary results. J. Neurol. Sci. 2003;. [in press].
53. Goodin D.S., Frohman E.M., Garmany G.P.et al. Disease modifyng therapies in multiple sclerosis. Neurology. 58:2002;169-178.
54. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43:1993;655-661.
55. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 45:1995;1277-1285.
56. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M.et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39:1996;285-294.
57. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 352:1998;1498-1504.
58. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P.et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 45:1995;1268-1276.
59. Comi G., Filippi M., Wolinsky J.S. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 49:2001;290-297.
60. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology. 56:2001;1496-1504.
61. Li D.K., Zhao G.J., Paty D.W. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology. 56:2001;1505-1513.